We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current PHBBF market cap is 3.45B. The company's latest EPS is CNY 0.8961 and P/E is 2.15.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 3.73B | 5.1B | 7.4B | 10.2B | 11.46B |
| Operating Income | 1.3B | 1.89B | 2.63B | 3.7B | 4.04B |
| Net Income | 547.19M | 1.17B | 1.66B | 1.37B | 1.6B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 9.94B | 11.91B | 18.39B | 20.49B | 26.48B |
| Total Liabilities | 2.1B | 2.98B | 8.09B | 9.65B | 13.24B |
| Total Equity | 7.84B | 8.93B | 10.3B | 10.84B | 13.24B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 938.59M | 1.65B | 2.06B | 2.14B | 2.75B |
| Investing | -1.05B | -3.37B | -5.26B | -2.21B | -2.25B |
| Financing | 4.25B | -280.18M | 3.66B | -1.42B | 3.92B |
| Market Cap | 3.45B |
| Price to Earnings Ratio | 2.15 |
| Price to Sales Ratio | 0.3 |
| Price to Cash Ratio | 0.6 |
| Price to Book Ratio | 0.26 |
| Dividend Yield | - |
| Shares Outstanding | 1.79B |
| Average Volume (1 week) | 100 |
| Average Volume (1 Month) | 100 |
| 52 Week Change | -14.22% |
| 52 Week High | 2.25 |
| 52 Week Low | 1.93 |
| Spread (Intraday) | 200k (100%) |
| Company Name | Pharmaron Beijing Company Ltd (PK) |
| Address |
8th floor, block 1 beijing 100176 |
| Website | https://www.pharmaron.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
